GeneDx (WGS) Competitors $81.45 -1.50 (-1.81%) Closing price 07/24/2025 04:00 PM EasternExtended Trading$80.88 -0.58 (-0.71%) As of 07/24/2025 07:52 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock WGS vs. GH, OPCH, RDNT, BTSG, SHC, SGRY, CON, PRVA, VCYT, and ARDTShould you be buying GeneDx stock or one of its competitors? The main competitors of GeneDx include Guardant Health (GH), Option Care Health (OPCH), RadNet (RDNT), BrightSpring Health Services (BTSG), Sotera Health (SHC), Surgery Partners (SGRY), Concentra Group Holdings Parent (CON), Privia Health Group (PRVA), Veracyte (VCYT), and Ardent Health (ARDT). These companies are all part of the "healthcare" industry. GeneDx vs. Its Competitors Guardant Health Option Care Health RadNet BrightSpring Health Services Sotera Health Surgery Partners Concentra Group Holdings Parent Privia Health Group Veracyte Ardent Health GeneDx (NASDAQ:WGS) and Guardant Health (NASDAQ:GH) are both mid-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their risk, analyst recommendations, valuation, profitability, media sentiment, dividends, institutional ownership and earnings. Do analysts recommend WGS or GH? GeneDx currently has a consensus price target of $92.33, suggesting a potential upside of 13.36%. Guardant Health has a consensus price target of $54.45, suggesting a potential upside of 19.70%. Given Guardant Health's stronger consensus rating and higher probable upside, analysts clearly believe Guardant Health is more favorable than GeneDx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score GeneDx 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Guardant Health 0 Sell rating(s) 0 Hold rating(s) 20 Buy rating(s) 1 Strong Buy rating(s) 3.05 Which has more volatility & risk, WGS or GH? GeneDx has a beta of 2.01, indicating that its stock price is 101% more volatile than the S&P 500. Comparatively, Guardant Health has a beta of 1.44, indicating that its stock price is 44% more volatile than the S&P 500. Do insiders and institutionals hold more shares of WGS or GH? 61.7% of GeneDx shares are owned by institutional investors. Comparatively, 92.6% of Guardant Health shares are owned by institutional investors. 29.6% of GeneDx shares are owned by company insiders. Comparatively, 6.1% of Guardant Health shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term. Does the media prefer WGS or GH? In the previous week, Guardant Health had 1 more articles in the media than GeneDx. MarketBeat recorded 16 mentions for Guardant Health and 15 mentions for GeneDx. GeneDx's average media sentiment score of 0.76 beat Guardant Health's score of 0.48 indicating that GeneDx is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment GeneDx 6 Very Positive mention(s) 0 Positive mention(s) 7 Neutral mention(s) 0 Negative mention(s) 1 Very Negative mention(s) Positive Guardant Health 6 Very Positive mention(s) 1 Positive mention(s) 1 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Is WGS or GH more profitable? GeneDx has a net margin of -11.69% compared to Guardant Health's net margin of -53.82%. GeneDx's return on equity of 10.17% beat Guardant Health's return on equity.Company Net Margins Return on Equity Return on Assets GeneDx-11.69% 10.17% 5.51% Guardant Health -53.82%N/A -26.77% Which has preferable earnings & valuation, WGS or GH? GeneDx has higher earnings, but lower revenue than Guardant Health. GeneDx is trading at a lower price-to-earnings ratio than Guardant Health, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioGeneDx$305.45M7.61-$52.29M-$1.41-57.77Guardant Health$739.02M7.63-$436.37M-$3.39-13.42 SummaryGuardant Health beats GeneDx on 9 of the 17 factors compared between the two stocks. Get GeneDx News Delivered to You Automatically Sign up to receive the latest news and ratings for WGS and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding WGS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart WGS vs. The Competition Export to ExcelMetricGeneDxMedical Services IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.37B$7.20B$5.73B$9.47BDividend YieldN/A2.80%4.60%3.99%P/E Ratio-57.7725.2027.9319.95Price / Sales7.6140.90438.49101.76Price / Cash81.0628.2736.5558.97Price / Book9.319.698.655.90Net Income-$52.29M$239.98M$3.24B$258.42M7 Day Performance4.60%2.63%3.71%2.12%1 Month Performance-8.41%5.86%10.34%12.46%1 Year Performance148.93%17.31%34.54%19.56% GeneDx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)WGSGeneDx4.0815 of 5 stars$81.45-1.8%$92.33+13.4%+140.7%$2.37B$305.45M-57.771,200Upcoming EarningsGHGuardant Health4.4586 of 5 stars$49.77-1.0%$53.76+8.0%+43.1%$6.17B$739.02M-14.682,021Upcoming EarningsAnalyst RevisionOPCHOption Care Health4.5947 of 5 stars$30.68+2.7%$35.50+15.7%-4.9%$5.02B$5.00B24.748,088Positive NewsUpcoming EarningsRDNTRadNet3.6755 of 5 stars$56.59+2.0%$69.60+23.0%-12.0%$4.25B$1.87B-131.6011,021Positive NewsBTSGBrightSpring Health Services1.9845 of 5 stars$20.31flat$24.90+22.6%+71.6%$3.57B$11.86B72.5435,000Upcoming EarningsSHCSotera Health3.2843 of 5 stars$11.61-1.6%$16.00+37.8%-9.5%$3.30B$1.10B145.143,000News CoveragePositive NewsSGRYSurgery Partners3.0928 of 5 stars$22.47+2.0%$33.56+49.3%-29.2%$2.88B$3.11B-14.6915,000CONConcentra Group Holdings Parent3.1717 of 5 stars$20.23+1.6%$28.50+40.9%N/A$2.59B$1.90B15.0911,250PRVAPrivia Health Group4.0985 of 5 stars$20.89+2.1%$28.38+35.9%+0.3%$2.55B$1.80B174.101,140Positive NewsVCYTVeracyte3.8086 of 5 stars$26.65-1.6%$40.90+53.5%+0.7%$2.09B$445.76M65.00790ARDTArdent Health3.7119 of 5 stars$14.51+2.4%$20.67+42.4%-35.5%$2.08B$5.97B8.9024,900 Related Companies and Tools Related Companies GH Competitors OPCH Competitors RDNT Competitors BTSG Competitors SHC Competitors SGRY Competitors CON Competitors PRVA Competitors VCYT Competitors ARDT Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:WGS) was last updated on 7/25/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredTreasury Secretary Bessent Is Betting Big on GoldWhen the U.S. Treasury Secretary’s largest personal investment is gold — that’s a signal. Now a veteran gol...Golden Portfolio | SponsoredYour blueprint for crypto wealthMark August 12th on your calendar. 27 of crypto's most successful minds are about to reveal everything…Crypto 101 Media | SponsoredTrump’s betrayal exposed Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredSpecial gold investment soars 2,300% ... 5,090% ... 9,850%In my 54 years as an investor, I’ve seen my share of gold bull markets. But nothing comes close to the rall...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding GeneDx Holdings Corp. Please log in to your account or sign up in order to add this asset to your watchlist. Share GeneDx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.